Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia.

ABSTRACT: Acute myeloid leukemia (AML) is a heterogeneous disease. A significant proportion of AML patients is refractory to clinical treatment or relapses. Our aim is to determine new potential AML clinical treatment prognosis markers. We investigated various cell fate and epigenetic regulation important gene level differences between refractory and responsive AML patient groups at diagnosis stage and after clinical treatment using RT-qPCR. We demonstrated that oncogenic MYC and WT1 and metabolic IDH1 gene expression was significantly higher and cell cycle inhibitor CDKN1A (p21) gene expression was significantly lower in refractory patients' bone marrow cells compared to treatment responsive patients both at diagnosis and after clinical treatment. Moreover, we determined

SUBMITTER: Vitkeviciene A 

PROVIDER: S-EPMC9179343 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature